

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **November 20, 2019**

**Heat Biologics, Inc.**

*(Exact name of registrant as specified in charter)*

**Delaware**

*(State or other jurisdiction of incorporation)*

**001-35994**

*(Commission File Number)*

**26-2844103**

*(IRS Employer Identification No.)*

**627 Davis Drive**

**Morrisville, North Carolina 27560**

*(Address of principal executive offices and zip code)*

**(919) 240-7133**

*(Registrant's telephone number including area code)*

**N/A**

*(Former Name and Former Address)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0002 par value per share	HTBX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement**

As previously announced, the Company’s subsidiary, Pelican Therapeutics, Inc. (“Pelican”), was awarded \$15.2 million to fund preclinical and certain clinical activities from Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”). The CPRIT Grant is subject to customary CPRIT funding conditions.

The CPRIT Grant initially covered a three-year period from June 1, 2017 through May 31, 2019. On April 12, 2019, CPRIT notified Pelican that it agreed to a six-month extension of time in order to conclude the approved scope of work, such that the completion date was extended from May 31, 2019 to November 30, 2019. On November 20, 2019, CPRIT notified Pelican that it agreed to a six-month extension of time in order to conclude the approved scope of work, such that the completion date was extended from November 30, 2019 to May 30, 2020. All other terms and conditions of the CPRIT arrangement remained the same.


**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:

Exhibit Number	Description
10.1*	<a href="#">Attachment F to CPRIT Contract</a>

\*Confidential portions of this exhibit have been omitted from the exhibit.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 22, 2019

HEAT BIOLOGICS, INC.

By: /s/ Jeffrey Wolf  
Name: Jeffrey Wolf  
Title: Chairman, President and  
Chief Executive Officer

---

## EXHIBIT INDEX


Exhibit Number	Description
10.1*	<a href="#">Attachment F to CPRIT Contract</a>

\*Confidential portions of this exhibit have been omitted from the exhibit.

**PORTIONS HEREIN IDENTIFIED BY [\*\*\*\*\*] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

Grant ID: DP160012  
 No Cost Extension with Attachment F

PI/PD/CR: Jeff Hutchins



As indicated by the signatures below, the INSTITUTE and the RECIPIENT agree to the following amendments to the CPRIT Contract:

**Original Contract End Date** : 31 May 2019

**Current Contract End Date** : 30 Nov 2019

**Proposed Contract End Date** : 30 May 2020

**Justification**: [\*\*\*\*\*].

**Contract Document F**: Parties hereby agree that the RECIPIENT is granted a second six-month extension of time from the termination date reflected in the Attachment F-No Cost Extension (Version 1) approved on April 12, 2019, for purposes of concluding the approved scope of work as authorized by the Contract. Accordingly, the November 30, 2019 termination date is replaced with May 30, 2020. All terms and conditions of the Contract continue during the extension period. Parties agree that this extension is a “no-cost” extension and approval of this amendment does not approve, grant or confer additional grant funds in excess of the amount originally awarded.

**Description** : The November 30, 2019 termination date is replaced with May 30, 2020 for purposes of concluding the approved scope of work as authorized by the Contract.

<p><b>RECIPIENT</b>                  Pelican Therapeutics  <b>ASO Name:</b> Jasuja, Rahul  <b>Submitted Date:</b> 09 Sep 2019</p>	<p><b>INSTITUTE</b>                  Cancer Prevention &amp; Research                  Institute of Texas  <b>CEO Name:</b> Roberts, Wayne  <b>Approved Date:</b> 20 Nov 2019</p>
---	---